NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded to “Hold” at Wall Street Zen
Wall Street Zen upgraded shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) from a sell rating to a hold rating in a research note published on Friday. Several other research firms have also recently issued reports on NAMS. Needham & Company LLC decreased their price objective on NewAmsterdam Pharma from $42.00 to $40.00 and set […]
Wall Street Zen upgraded shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) from a sell rating to a hold rating in a research note published on Friday. Several other research firms have also recently issued reports on NAMS. Needham & Company LLC decreased their price objective on NewAmsterdam Pharma from $42.00 to $40.00 and set […]
